UBS initiated coverage of Inventiva (IVA) with a Neutral rating and $3 price target The firm thinks the company’s pan-PPAR agonist lanifibranor, currently in Phase 3 for metabolic dysfunction-associated steatohepatitis with fibrosis stage 2 or 3, has shown “promising” Phase 2 data and as an oral could take a piece of the large MASH market. However, with Phase 3 data expected in the second half of 2026, UBS sees the next two years as an execution period for Inventiva.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IVA:
- Inventiva’s Strategic Moves at Upcoming General Meeting
- Inventiva Gains Positive Nod for Lanifibranor Trial
- Inventiva announces DMC recommendation to continue NATiV3 trial as is
- Inventiva’s 2024 Interim Financial Highlights and Prospects
- Inventiva price target lowered to $13 from $14 at H.C. Wainwright